SP acquires Spain based global provider of complete sterile filling lines
Company's strategic move reflects its expectation of short-run aseptic liquid filling to continue to drive pharmaceutical growth.
SP Industries has acquired the assets of privately held i-Dositecno. Located in Mataro, Spain, i-Dositecno is a global provider of complete sterile filling lines for pharmaceutical, cosmetic and ophthalmic applications.
“i-Dositecno has a well-earned reputation for producing high quality, fill-finish equipment complemented by strong software engineering capabilities and innovative servicing and support,” stated SP CEO Brian Larkin.
“At SP we are continually focused on bringing value to our customer relationships and i-Dositecno’s current portfolio, engineering expertise and broad capabilities in liquid filling particularly for syringes and other cartridges in addition to vials, are a very strategic complement to our Hull and VirTis freeze dryers and PennTech aseptic vial processing lines.”
Larkin continued: “As biological drug development and treatment protocols have become more specialized, we expect short-run aseptic liquid filling to continue to drive pharmaceutical growth. With the addition of i-Dositecno to our SP brand, we now join a very select group of manufacturers with the capability to provide full lines. And, while SP has traditionally had a stronger equipment footprint in the US, i-Dositecno’s efforts and success have primarily been within Europe and Asia. These relationships, as well as the addition of a Spain location to our current UK manufacturing within Europe provide significant opportunity to better serve the worldwide market. Key manufacturing, engineering, sales and service personnel from i-Dositecno have joined the SP team to assure continuity in operations and service. Oriol Casoliva, founder and past CEO of i-Dositecno will join SP’s Executive Leadership Team and we look forward to benefiting from his vision and depth of knowledge in maximizing i-Dositecno and SP’s performance within the aseptic pharmaceutical manufacturing space.“
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance